Soliton Initiated Clinical Trials for Cellulite Treatment

Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today summarized its efforts to conduct a proof of concept clinical trial for the treatment of cellulite based on Institutional Review Board (“IRB”) approval of the study.  The study was initiated after positive results in animal studies indicated the potential for a higher-energy version of its acoustic shockwave technology to affect the factors contributing to the formation of cellulite.

The study treated each thigh of five patients (n=10) with a higher-energy version of Soliton’s acoustic shockwave device with the intent to evaluate safety and efficacy in the treatment of cellulite.  The study is designed to evaluate results at both the 12-week and 26-week timepoints from initial treatment in order to assess both near-term and long-term effects.

https://www.prnewswire.com/news-releases/soliton-initiated-clinical-trials-for-treatment-of-cellulite-in-humans-300821569.html